UCB to showcase broad immunology portfolio at EULAR 2012 MarketWatch (press release) Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA ... |
